The IDEXX Cancer Dx panel provides accurate detection of biomarkers specific for lymphoma and mast cell tumor in canine whole blood and serum. B-cell vs. T-cell phenotype classification will be provided with positive lymphoma results as available at no additional cost. 

The Cancer Dx panel is primarily intended to complement existing oncology diagnostics as a screening offering, by adding capability to detect disease in healthy-appearing at-risk dogs. It is not intended to replace existing tools which are relevant once clinical signs are apparent. IDEXX recommends Cancer Dx at wellness visits for at-risk dogs.

The Cancer Dx lymphoma test, which is available as a single-cancer test, is suitable for use in disease monitoring and as an aid in diagnosis, in addition to the primary screening use case for the panel as a whole.

At-risk dogs include all breeds aged 7+ and breeds at increased risk for cancer aged 4+. Breeds at increased risk for lymphoma: beagle, Bernese mountain dog, boxer, bullmastiff, Doberman pinscher, English bulldog, flat-coated retriever, French bulldog, golden retriever, Labrador retriever, miniature schnauzer, rottweiler, and Scottish terrier. Breeds at increased cancer risk also include: Boston terrier, Chinese pug, German shepherd, Irish wolfhound, Pembroke Welsh corgi, Rhodesian ridgeback, Scottish deerhound, shar-pei, Siberian husky, and weimaraner.

2 mL of serum and 1 mL of EDTA whole blood, whether run standalone, as an add-on, or in a profile. When run with chemistry and CBC, it uses a portion of the same 2 mL serum/1 mL EDTA specimens — no separate tubes needed.

Results are reported as either "positive" or "negative" for each of the cancer tests within the panel. If a result can't be obtained, the customer is notified in their results view.